The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2021 | 1L FOLFOXIRI plus cetuximab or bevacizumab for RAS wild-type mCRC
Yu Sunakawa, MD, PhD, St. Marianna University School of Medicine, Kawasaki, Japan, talks on the findings of the DEEPER trial, evaluating the efficacy and safety of bevacizumab versus cetuximab in combination with FOLFOXIRI in previously untreated metastatic colorectal cancer (mCRC) patients with RAS wild-type tumors. Modified FOLFOXIRI plus cetuximab has been shown to be significantly superior to the modified FOLFOXIRI plus bevacizumab in terms of depth of response in the treatment of first-line (1L) mCRC. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
Disclosures
Yu Sunakawa, MD, PhD has received grants and personal fees from Taiho Pharmaceutical, Chugai Pharma, Takeda, Eli Lilly Japan, and Sanofi; personal fees from Bayer Yakuhin, Yakult Honsha, Bristol-Myers Squibb Japan, Merck Biopharma, Ono Pharma, MSD, Daiichi Sankyo; and grants from Otsuka.
